Company profile
Eli Lilly
Diversified pharma
Share price · LLY
$1225.73+237.64 (+24.05%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(60 total)
60Total Assets
26Approved
13Phase 3 / Filed
21Phase 1–2 / Early
20Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | CDK4 and CDK6Small molecule | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | Undisclosed / early pipeline · Thymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTSmall molecule | Non-Small Cell Lung Cancer | |
baricitinib(Olumiant) | Approved | JAK · JAK1/2Small molecule | Atopic DermatitisRheumatoid Arthritis |
Donanemab(Kisunla) | Approved | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
dulaglutide(Trulicity) | Approved | GLP-1 receptorPeptide | Type 2 DiabetesAtherosclerotic Cardiovascular Disease |
Duloxetine(Cymbalta) | Approved | Serotonin/norepinephrine transporter · Serotonin and norepinephrine transporters (SERT/NET)Small molecule | Diabetic Peripheral Neuropathic Pain |
Empagliflozin(Jardiance) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
| Approved | ribonucleotide reductase / DNA polymerase (dCTP competition)Small molecule | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | Estrogen receptorSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Insulin Lispro(Humalog) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
insulin NPH(Humulin N / Novolin N) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
ixekizumab(Taltz) | Approved | IL-17Monoclonal antibody | Psoriatic ArthritisAtopic DermatitisPsoriasis |
lebrikizumab(Ebglyss) | Approved | IL-13Monoclonal antibody | Atopic Dermatitis |
Linagliptin(Tradjenta) | Approved | DPP-4Small molecule | Type 2 Diabetes |
LY2963016(Basaglar) | Approved | Insulin receptor (basal)Peptide | Type 2 Diabetes |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.